Rational design of amphiphile-based drug carriers and sterically stabilized carriers

Abstract

This paper describes the parameters recommended for rational design of amphiphile-based drug carriers. The main advantage of a carrier is its ability to modify the pharmacokinetics and biodistribution of the drug, so that the drug level at the target is sufficient for therapeutic benefits. Three parameters are described. Two of them, the drug-to-carrier partition coefficient (KyiC) and the rate of drug release from the carrier (kff), are related to drug-carrier interactions; the third one is the rate of carrier clearance (kc). We demonstrate that carrier performance for drugs associated with the carrier amphiphile(s) is determined to a large extent by Kc, while for drugs encapsulated in the aqueous phase of the carrier it is important that koff will be similar to kc These conclusions are based on two examples: (i) Amphotericin B as a drug associated with five dosage forms which represent different types of amphiphile-based carriers: micelles (Fungizone), stable micelle-like disks (Amphocil), a complex with phospholipids (ABPLC), liposomes (AmBisome), and a submicronized emulsion, (ii) Liposomal doxorubicin which consisted of either doxorubicin associated with the membrane of negatively-charged, fluid oligolamellar liposomes (L-DOX) or doxorubicin loaded by an ammonium sulfate gradient into small, unilamellar, rigid liposomes having steric stabilizing lipid grafted in their lipid bilayer, (S-DOX). To better understand what contributes to k, we also describe the effect of bilayer acyl chain composition and the role of precipitation of the drug inside the liposomes.